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New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed. 
When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the 
dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic 
migration pattern. Using biochemical assays, computer-aided docking/molecular dynamics simulations, and 
fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes 
(α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the 
endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1. RSV was also predicted 
to interact with the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the 
target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1. The ability of RSV to 
directly target PD-L1 interferes with its stability and trafficking, ultimately impeding its targeting to the cancer cell 
plasma membrane. Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte 
activity was notably exacerbated when cancer cells were previously exposed to RSV. This unforeseen 
immunomodulating mechanism of RSV might illuminate new approaches to restore T-cell function by targeting the 
PD-1/PD-L1 immunologic checkpoint with natural polyphenols.  
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INTRODUCTION 
 
Unlike immunologically “hot” tumors such as lung 
cancer, melanoma, and bladder cancer, most breast 
carcinomas are not inherently immunogenic. Con-
sequently, they typically exhibit low T-cell infiltration 
and are unlikely to benefit from immune checkpoint-
centric therapies [1–5]. Exceptions to this immuno-
logically “cold” rule of breast carcinomas are the so-
called basal-like [6–14] and HER2-positive [15–20] 
subtypes, both of which show evidence of 
immunogenicity including tumor immune infiltrates and 
stromal and intratumoral tumor-infiltrating lympho-
cytes, a good predictive marker for responses to 
immunotherapy. Correspondingly, the otherwise rare 
expression in most breast carcinomas of programmed 
death ligand-1 (PD-L1) – an archetypal immuno-
suppressive molecule on cancer cells that engages its 
receptor PD-1 on T-cells to suppress T-cell-mediated 
immune surveillance [21–23] – is markedly enriched in 
basal-like and HER2-positive tumors, thereby implying 
that PD-L1 confers a survival advantage in the tumor 
microenvironment (TME) of these specific breast 
cancer subtypes. However, the response rates reported 
in clinical trials for breast cancer with PD-1/PD-L1 
checkpoint inhibitors as single agents have been rather 
disappointing (5–10%), although better clinical 
activities (up to 30%) and durable overall responses 
have been observed in patients with basal-like/HER2+ 
breast cancer and positive expression of PD-L1 [24–
29]. Accordingly, the identification of new strategies 
to block the immune-inhibitory signal of PD-L1 in 
basal-like and HER2-positive subtypes is urgently 
needed.  
 
In recent years, the cancer immunometabolism field has 
started to provide important insights into the pivotal role 
of metabolism in controlling immune cell function [30–
35]. Indeed, much is now known about how the 
phenotypic switching of T-cells to be effective against 
tumor cells necessarily requires metabolic specialization, 
and how specific metabolic activities and tumor-driven 
shifts in the abundance of specific metabolites shape 
local immunosuppression and reduce the metabolic 
fitness of tumor-infiltrating lymphocytes. Indeed, the 
inhibitory nature of the metabolic interplay between 
tumor and immune cells in the TME supports its 
suitability as a target to overcome the immune escape of 
cancer cells and circumvent immunotherapy resistance. 
Accordingly, various combinations of immunotherapies 
with metabolic agents aimed to rewire T-cell fitness – by 
suppressing the immunosuppressive metabolic traits 
within the TME – are being tested in clinical trials  
[36–39]. Nonetheless, the appraisal of cancer cell-
autonomous metabolic reprogramming as a bona fide 
driver of immune checkpoint signaling in tumor cells is a 
largely neglected area in cancer immunometabolism. 
Indeed, we are lacking even a minimal understanding of 
how pharmacological manipulations targeting core 
metabolic checkpoints such as AMPK, mTOR, and 
SIRT1, might fine-tune the expression of immune 
checkpoint receptors in cancer cells.  
 
Here, we took advantage of the JIMT-1 cell line, a unique 
model of highly-aggressive basal-like/HER2-positive 
breast cancer naturally overexpressing the immuno-
suppressive molecule PD-L1 with 100% of the cells 
positive for PD-L1 [40], to explore the potential 
regulatory effects of mechanistically diverse metabolism-
targeting drugs on PD-L1. By combining biochemical, 
computational, and microscopy approaches with label-
free monitoring of T-cell activation, we provide the first 
evidence that the dietary polyphenol resveratrol (RSV) 
can directly target PD-L1 glycosylation and dimerization 




Resveratrol increases the electrophoretic mobility of 
PD-L1 protein 
 
PD-L1 is a type I transmembrane glycoprotein with an 
apparent molecular weight of ~45 kDa. We first 
examined the protein expression of PD-L1 in JIMT-1 
cells cultured with the following metabolism-targeting 
drugs: the SIRT1 agonist RSV, the mitochondrial 
complex I inhibitor phenformin, the acetyl-coA 
carboxylase inhibitor soraphen A, the fatty acid 
synthase inhibitor C75, and the AMPK/mTOR 
regulators AICAR, compound C, PP242, and Torin 
(Figure 1A). Based on three independent experiments 
aimed to reflect the substantial variation of PD-L1 
expression by multiple parameters including cell 
density, both phenformin and AICAR consistently 
downregulated the major PD-L1 form at ~45 kDa. By 
contrast, treatment with RSV increased the electro-
phoretic mobility of PD-L1, which led to the 
conspicuous appearance of an intense immunoreactive 
band with a slightly lower molecular size (Figure 1A).  
 
Resveratrol disrupts N-linked glycosylation of PD-L1 
 
Previous studies have unambiguously demonstrated that 
the ~45 kDa form of PD-L1 corresponds to the fully N-
glycosylated mature protein [41–43]. As glycosylation 
of proteins often generates a heterogeneous migration 
pattern on immunoblots, such as that observed for PD-
L1 in response to RSV treatment, we hypothesized that 
RSV might promote the accumulation of an aberrantly-
glycosylated form of PD-L1. To test this, we re-
evaluated the expression of PD-L1 in cells cultured with 
the antibiotic tunicamycin, which blocks N-linked 
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glycosylation by inhibiting the enzyme N-
acetylglucosamine phosphotransferase, responsible for 
the initial steps in protein glycosylation (Figure 1B). A 
significant portion of the major ~45-kDa PD-L1 band 
was reduced to ~33 kDa upon tunicamycin treatment in 
control (RSV-untreated) cell cultures, which is known 
to represent the non-glycosylated form of PD-L1. The 
molecular weight shift to non-glycosylated PD-L1 was 
more evident in cells co-treated with RSV and 
tunicamycin, and the addition of tunicamycin also 
prevented the accumulation of the lower PD-L1 band 
that appeared in response to RSV as a single agent 
(Figure 1B). Also, in the presence of the protein 
synthesis inhibitor cycloheximide, the turnover of the 
RSV-induced smaller species of PD-L1 and of the non-
glycosylated (~33 kDa) form of PD-L1 appeared to be 





Figure 1. PD-L1 is abnormally glycosylated in response to resveratrol. (A) Representative immunoblot of PD-L1 protein in JIMT-1 
cells cultured with or without metformin (1a), phenformin (1b), RSV (2), soraphen A (3), C75 (4), PP242 (5), Torin (6), AICAR (7), or compound 
C (8). (B, D) Representative immunoblots of PD-L1 protein in JIMT-1 cells cultured in the absence of presence of RSV, tunicamycin (TM), 
cycloheximide (CHX), chloroquine (CLQ), and/or MG-132. (C) PD-L1 glycosylation patterns obtained from cell lysates of RSV-treated or 
untreated control cells that were further treated with PNGase F and Endo H and analyzed by western blotting. (C: untreated control; black 
arrowhead, glycosylated PD-L1; *orange arrowhead, abnormal glycosylated PD-L1 form; **orange arrowhead, non-glycosylated PD-L1).  
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Whole cell lysates obtained from JIMT-1 cells cultured 
in the absence or presence of RSV were further 
incubated with either N-glycanase (PNGase F), which 
removes all types of N-linked (asparagine-linked) 
glycosylation (i.e., high mannose, hybrid, bi-, tri-, and 
tetra-antennary) or endoglycosidase H (Endo H), which 
removes only high mannose and some hydrid types of 
N-linked oligo-saccharides. Similar to the results with 
tunicamycin, PNGase F-driven removal of all N-linked 
glycan chains without regard to type completely 
blocked PD-L1 glycosylation irrespective of the 
absence or presence of RSV, as indicated by the 
conversion of the original pattern of PD-L1 post-
translational glyco-modification to a discrete band 
corresponding to the non-glycosylated (~33 kDa) form 
(Figure 1C). By contrast, the addition of recombinant 
Endo H, which is known to cleave the high-mannose N-
linked oligosaccharides found in the endoplasmic 
reticulum (ER), specifically prevented the aberrant 
glycosylated form of PD-L1 induced by the presence of 
RSV (Figure 1C).  
 
Our results so far strongly suggest that the fraction of 
PD-L1 with a slightly lower molecular weight occurring 
in response to RSV is a non-fully, abnormally 
glycosylated form of PD-L1. Because PD-L1 protein 
stability is greatly influenced by its glycosylation state 
[41], we next determined the impact of the proteasome 
inhibitor MG-132 and the lysosomal inhibitor 
chloroquine on the RSV-induced faster migrating form 
of PD-L1. The abnormally glycosylated RSV-induced 
form of PD-L1 completely disappeared after treatment 
with MG-132 (Figure 1D), whereas chloroquine 
treatment notably protected the conspicuous PD-L1 
migration pattern induced by RSV (Figure 1D).   
 
Resveratrol directly targets N-linked glycan 
decoration of PD-L1 
 
To substantiate that the RSV-induced aberrant 
glycosylated form of PD-L1 occurred concomitantly 
with the expected mode(s) of action of RSV, we first 
confirmed the well-known capacity of RSV to induce 
the endogenous expression of SIRT1 protein [42–44] 
(Figure 2A, left panels). Likewise, consistent with the 
ability of RSV to bind and inhibit histone HDAC 
enzymes [45, 46], RSV-treated JIMT-1 cells also 
showed increased p53 acetylation at lysine 382 [47]. 
The effects of RSV on PD-L1 glycosylation were 
neither prevented by the concurrent presence of the 
AMPK inhibitor compound C, nor by co-treatment with 
the SIRT1 inhibitor EX-527 [48] (Figure 2A, left 
panels). Moreover, the GSK3β inhibitors AR-18 
(Figure 2A, middle panels) and LiCL (Figure 2A, right 
panels) failed to reverse the RSV-induced migration  
 
pattern of PD-L1, thereby ruling out the possibility 
that RSV might indirectly disrupt N-linked glyco-
sylation through GSK3β activation [49] (Figure 2A, 
right panels).  
 
These findings are consistent with a direct (and SIRT1-, 
AMPK-, GSK3β-independent) effect of RSV on the 
PD-L1 N-linked glycosylation machinery (Figure 2B). 
Indeed, RSV treatment notably mimicked the ability of 
inhibitors blocking N-linked (but not O-linked) 
glycosylation (e.g., swainsonine, castanospermine, 
kifunensin, or 1-deoxy-mannojirimycin) to alter the 
migration pattern of glycosylated PD-L1 on SDS-PAGE 
[50]. Specifically, the capacity of RSV to operate as an 
antiglycation agent via direct inhibition of α-
glucosidase I (GAA) [51–54] and/or α-mannosidase I 
(α-Man I) [55, 56] would suffice to explain the ability 
of RSV to generate an Endo H-sensitive, high-mannose 
N-linked glycan form of PD-L1 in the ER (Figure 2B). 
In an attempt to provide a computational explanation for 
the inhibitory activity of RSV against GAA, we 
performed molecular docking and molecular dynamics 
(MD) assays of RSV against high-resolution crystal 
structures of the yeast (4J5T [57]) and human (5NN4 
[58]) forms of GAA. RSV was predicted to occupy the 
catalytic site of yeast GAA with a higher binding 
energy than that predicted for acarbose, a well-known 
competitive inhibitor of GAA [59–63] (Figure 3A–3C; 
supplementary information, Supplementary Figure S1 
and Table S1). Conversely, several RSV clusters were 
predicted to interact with enzymatic pockets distant to 
the active site of human GAA (Figure 4, top panels), 
which was accurately predicted to be occupied by 
acarbose (Figure 4, bottom panels; Supplementary 
Table S2). When we extended the in silico studies to α-
Man I (i.e., ER 1,2-α-mannosidase (5KIJ) [64]), the sole 
RSV cluster predicted to interact with α-Man was found 
to occupy the catalytic site of the enzyme and exhibited 
a binding energy even higher than that predicted for 
kifunensin, a well-known pharmacological inhibitor of 
α-Man I [65, 66] (Figure 5A; Supplementary Table S3). 
Although the generation of a homology model of α-Man 
II predicted the ability of numerous clusters of RSV to 
interact with several enzymatic pockets including the 
active site (Figure 5B), the energy binding was lower 
than that predicted for α-Man I. Considering both the 
trajectories and the solvation/binding free energy 
differences (supplementary information, Supplementary 
Figure S2) of the different RSV-enzyme complexes 
following MD simulations up to 100 ns, the 
computational behavior of RSV was compatible with 
that of a non-competitive inhibitor bound to allosteric 
sites in the case of human GAA and of a competitive 
inhibitor capable of stably occupying the catalytic site 
in the case of human α-Man I.   
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Resveratrol inhibits the cell membrane localization 
of glycosylated PD-L1 
 
We next investigated whether the ability of RSV to 
target PD-L1 glycosylation altered PD-L1 membrane 
trafficking. Light microscopy observations suggested 
that RSV induced a hypertrophy-like phenotype in 
treated JIMT-1 and MDA-MB-231 cells (Figure 6, top 
panels), a second PD-L1-overexpressing breast cancer 
model representative of the basal-like subtype [40, 67, 
68] as indicated by the transformation of spindle-shaped  
control cells to more enlarged, irregular, and flattened 
cell morphologies after switching to culture medium with 
RSV (Figure 6, top panels). Also, immuno-fluorescence 
microscopy using an antibody directed against an 
intracellular epitope of PD-L1 showed PD-L1 enrichment 
both in the plasma membrane and in specific cytoplasmic 
vesicular-like compartments (Figure 6, bottom panels). A 
more detailed analysis showed that cell membrane PD-L1 
signals were clearly diminished in response to RSV, and 
this was accompanied by an increase in the number of 




Figure 2. Resveratrol alters PD-L1 N-glycosylation in a SIRT1-, AMPK-, and GSK3β-independent manner. (A) Representative 
immunoblot of SIRT1, acetyl-p53 (Lys382), and PD-L1 in JIMT-1 cells cultured with or without RSV in the absence or presence of the AMPK 
inhibitor compound C, the SIRT1 inhibitor EX-527, and the GSK3β inhibitors AR-18 and LiCl. (B) Schematic representation of the biosynthesis 
and processing PD-1 N-linked glycosylation pathway, showing the sites of action of well-known glycoprotein-processing enzymes inhibitors. 
RSV is proposed to operate as a direct inhibitor of GAA and/or α-Man I enzymatic activities.  
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The RSV-driven cell membrane-to-cytoplasm 
redistribution of PD-L1 was more apparent when we 
used an antibody specifically directed to the 
extracellular domain of PD-L1, revealing an evident 
decrease in cell membrane-associated PD-L1 and the 
apparent retention of PD-L1 in perinuclear com-
partments with a punctate staining pattern (Figure 6, 
bottom panels). 
 
Resveratrol lowers the tumor cytotoxicity threshold 
to T-cells 
 
Finally, we questioned whether RSV-induced abnormal 
glycosylation of PD-L1 would increase the 
susceptibility of basal-like/HER2+ breast cancer cells to 
T-cell elimination. To do this, we used an impedance- 




Figure 3. Resveratrol is predicted to bind the catalytic site of yeast GAA. Surface and backbone representations of yeast GAA 
showing the computationally predicted location of acarbose (A) and RSV (B) clusters. “Site A” refers to the pocket containing the proposed 
catalytic residues of yeast GAA whereas “site B” refers to a second cavity roughly 12 Å away from the active site pocket of yeast GAA [57]. (C) 
A detailed map of the molecular interactions of RSV in each cluster before (0 ns) and after 100 ns of molecular dynamics simulation. Each 
inset shows the detailed interactions of each RSV cluster docked to yeast GAA using the PLIP algorithm [124], indicating the participating 
amino acids involved in the interaction and the type of interaction (hydrogen bonds, hydrophilic interactions, salt bridges, Π-stacking, etc). 
Figures were prepared using PyMol 2.3 software. 
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label-free assessment of T-cell-mediated killing of PD-
L1-expressing JIMT-1 cells [69, 71]. Briefly, impedance 
(or opposition) to an electric current occurs when adherent 
(tumor) cells bind to electrode plates; conversely, 
electrical impedance is reduced when tumor cells detach 
following killing, which can be measured by the real-time 
cell analyzer. The addition of T-cells in suspension over a 
monolayer of adherent tumor cells does not influence the 
impedance measurements as they do not contact with the 
electronic sensor; however, we could specifically detect  
T-cell activation events as the induction of T-cell-
mediated tumor cell death results in morphological and 
detachment events that can readily be detected via 
changes in impedance. At a T-cell-to-cancer cell ratio of 
5:1, we observed cytolytic activities as low as 15–17% 
following the addition of T-cells to JIMT-1 cells (Figure 
7). When JIMT-1 cells were pre-treated with RSV before 
exposure to T-cells, we observed a significantly more 
robust cytolytic activity that reached >50% of the tumor 
cell population (Figure 7). 
 
 
Figure 4. Resveratrol is predicted to bind allosteric sites in the surface of human GAA. Surface and backbone representations of 
human GAA showing the computationally-predicted location of RSV (top panels) and acarbose (bottom panels) clusters. A detailed map of 
the molecular interactions of RSV and acarbose in each cluster before (0 ns) and after 100 ns of molecular dynamics simulation. Each inset 
shows the detailed interactions of each RSV/acarbose cluster docked to human GAA using the PLIP algorithm [124], indicating the 
participating amino acids involved in the interaction and the type of interaction (hydrogen bonds, hydrophilic interactions, salt bridges, Π-
stacking, etc). Figures were prepared using PyMol 2.3 software. 
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RSV is predicted to target PD-L1 dimerization 
 
The strong exacerbation of the cytotoxic activity of T-
cells against RSV-treated cancer cells raised the 
suspicion that additional PD-L1-targeted RSV 
mechanisms of action might be involved. We speculated 
that such non-mutually exclusive mechanisms might 
involve RSV binding to the dimerization surface of PD- 
L1, which is the same employed by PD-L1 to interact 
with PD-L1 [71–77]. Computer-aided docking/MD 
simulations predicted the capacity of RSV to occupy the 
cavity formed by two PD-L1 monomers (ΔG=-9.252 
kcal/mol) in a manner closely mimicking that of BMS-
202 (ΔG=-11.11 kcal/mol), a small-molecule capable of 
inhibiting the PD-1/PD-L1 interaction by inducing PD-




Figure 5. Resveratrol is predicted to bind the catalytic site of human α-mannosidases. Surface and backbone representations of 
human α-Man I (A) and homology model of human α-Man II (B) showing the computationally predicted location of RSV clusters. A detailed 
map of the molecular interactions of RSV in each cluster before (0 ns) and after 100 ns of molecular dynamics simulation. Each inset shows 
the detailed interactions of each RSV cluster docked to human GAA using the PLIP algorithm [124], indicating the participating amino acids 
involved in the interaction and the type of interaction (hydrogen bonds, hydrophilic interactions, salt bridges, Π-stacking, etc). The white 
inset in A shows a surface and backbone representations of human α-Man I docked to the α-Man I inhibitor kifunensine. Figures were 
prepared using PyMol 2.3 software. 
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Figure 6. Resveratrol alters the sub-cellular expression pattern of PD-L1. Representative immunofluorescence staining of PD-L1 in 
JIMT-1 (left panels) and MDA-MB-231 (right panels) breast cancer cells cultured in the absence or presence of RSV, using an antibody 




Figure 7. Resveratrol enhances the susceptibility to T-cell-mediated tumor cell killing. T-cell-mediated cell death of JIMT-1 cells 
pre-cultured in the absence of presence of RSV was measured using the xCELLigence system. Shown are the mean (±SD, n=3) of % lysis values 
calculated from the impedance-based lysis assay at 5 and 10 hours following the addition of T-cells. Also shown are microphotographs of 
representative T-cell-mediated cancer cell killing assays in which tumor cells were subjected to crystal violet staining. Statistical analysis was 
performed using GraphPad Prism 7, using two-way ANOVA with Sidak’s multiple comparison post-test, comparing untreated versus RSV-
treated per time (* = P < 0.01).   
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[71, 75] (Figure 8, top). The interacting mode of RSV 
with the dimeric PD-L1 complex included the key 
contribution of Ile54, Tyr56, Met115, Ala121, and 
Tyr123 residues on both monomers. An analysis of the 
RSV trajectory docked to the PD-L1 dimerization 
interface during a 100 ns period revealed a less than 5Å 
displacement compared with its initial position at the 
PD-L1 interaction interface (Figure 8, bottom). These 
findings, together with solvation binding energies as 
high as 45 kcal/mol, provided computational insight 
into the putative capacity of RSV to target PD-L1 
dimerization and block the PD-1/PD-L1 interaction. 
When we examined monomeric and dimeric 
conformations of PD-L1 by native gel electrophoresis, 
the presence of appreciable amounts of PD-L1 dimer 
was apparent in RSV-treated cells whereas the 
monomeric form of PD-L1 was the major species in 




Figure 8. Resveratrol is predicted to bind the PD-1 dimer interface. Top Backbone representation of the PD-L1:PD-L1 dimer showing 
the computationally-predicted location of RSV (yellow) and BMS-202 (cyan). Chain A shows the location of the four Asn residues that can be 
glycosylated. The insets show the detailed maps of the molecular interactions of RSV with the amino acids at the hydrophobic pocket 
accommodating the BMS-202 inhibitor and formed at the PD-L1 dimer surface before (0 ns) and after 100 ns of molecular dynamics (MD) 
simulation, indicating the participating amino acids involved in the interaction and the type of interaction (hydrogen bonds, hydrophilic 
interactions, salt bridges, Π-stacking, etc). Bottom. Left. Trajectory of the RSV-forming complex with the PD-L1 dimer. Right. Molecular 
Mechanics/Poisson-Boltzmann Surface Area free energy analysis of the PD-L1 dimer forming a complex with RSV using YASARA dynamics 
v19.9.17 software. The best-docked complex as the initial conformation for MD simulation followed by 1000 snapshots (100 ns) obtained 
from the MD trajectory were employed to calculate the values of free energy binding of RSV. Additionally, the average value calculated for 
the last 200 snapshots (20 ns) is also displayed. YASARA-calculated binding energy provides positive values when the predicted binding is 
strong and stable whereas negative values indicate no binding. Figures were prepared using PyMol 2.3 software.  
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DISCUSSION 
 
We provide the first demonstration that RSV targets the 
immune evasion capacities of cancer cells by directly 
disrupting N-glycan branching and promoting 
dimerization of PD-L1, thereby impeding the correct 
localization of PD-L1 to the plasma membrane, 
preventing the PD-1 interaction surface of PD-L1 and, 
consequently, increasing the susceptibility of bio-
logically aggressive cancer cells to T-cell-mediated cell 
death (Figure 9).  
 
The recently discovered ability of the mitochondrial I 
inhibitor metformin to target PD-L1 in cancer cells [67] 
provides support to the notion that the cancer cell-auto- 
nomous metabolic status can shape the composition of 
immune checkpoints in cancer cells. The activated form 
of AMPK generated in response to the metabolic crisis 
induced by metformin has been found to directly 
phosphorylate PD-L1 in a manner that promotes its 
abnormal glycosylation, resulting in ER accumulation 
and ER-associated protein degradation [39, 67]. We here 
characterized the unforeseen ability of RSV to disrupt N-
linked glycosylation of PD-L1 and consequently reduce 
PD-L1 maturation and, ultimately, hamper its cancer cell 
surface-associated expression. Unlike metformin, 
however, the ability of RSV to generate a high mannose, 
abnormally glycosylated form of PD-L1 does not rely on 
its SIRT1-activating activity and also appears not to 




Figure 9. Resveratrol enhances antitumor T cell immunity by promoting abnormal glycosylation and dimerization of PD-L1. 
Post-translational modifications such as glycosylation, phosphorylation, palmitoylation or ubiquitination are essential for the folding, 
intracellular transport, and stabilization of the PD-L1 protein [41, 110–114]. PD-L1 is highly glycosylated, and N-linked glycosylation of PD-L1 
critically maintains its protein stability and is required for its interaction with PD-1 to efficiently suppress T-cell activity. Recently, Bristol-
Myers Squibb (BMS)-developed compounds with a common (2-methyl-4-biphenylyl)methanol scaffold have been reported to block the PD-
1/PD-L1 interaction by interacting with the cavity formed by the two PD-L1 monomers and inducing the dimerization of PD-L1 [71–77]. 
Structural studies have revealed a dimeric protein complex with a single small molecule that stabilizes the dimer and thereby occludes the 
PD-1 interaction surface of PD-L1. We propose that RSV is a naturally occurring, double-strike PD-1/PD-L1 immune checkpoint inhibitor 
capable of directly blocking the enzymatic machinery in charge of the N-linked glycosylation of the nascent PD-L1 at the endoplasmic 
reticulum or directly binding to PD-L1 surfaces to induce PD-L1 dimerization and block PD-1 binding. This unforeseen ability of RSV to directly 
interfere with PD-L1 stability and trafficking impedes the correct targeting of PD-L1 to the cancer cell plasma membrane and ultimately elicits 
drastically enhanced cytotoxic T-lymphocyte immune-surveillance against tumor cells. These findings might illuminate new approaches to 
restore T-cell function by targeting the PD-1/PD-L1 immunologic checkpoint with natural polyphenols. 
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positive feedback between AMPK and SIRT1 [78–80]. 
Rather, RSV likely operates as a direct inhibitor of 
glycoprotein-processing enzymes such as GAA and α-
Man I (Figure 6), which trim terminal glucoses and 
mannose from nascent PD-L1, a crucial process for 
proper PD-L1 protein folding [81, 82]. The finding that 
the occurrence of the Endo H-sensitive abnormal 
glycosylated form of PD-L1 induced by RSV was 
diminished by the protein synthesis inhibitor 
cycloheximide, completely cleared by the proteasome 
inhibitor MG-132, and notably protected by the 
autophagy inhibitor chloroquine, altogether support a 
mechanism of action in which: 1) RSV might directly 
hinder GAA/α-Man I-driven trimming of glucoses and 
mannose immediately after the lipid-linked oligo-
saccharide precursor is transferred to Asn residues of 
nascent PD-L1 protein. Such a direct blockade of key 
glycoprotein-processing enzymes prevents the PD-L1 
glycoprotein from attaining its native conformation 
because GAA and α-Man I ensure that, after correct 
folding, the processed (high-mannose) PD-L1 
glycoprotein can move to the Golgi where N-linked 
glycans can be further remodeled; 2) The consequent 
imbalance between the amount of unfolded/misfolded 
PD-L1 protein in the ER lumen and the capacity of the 
ER machinery to refold the population of aberrantly 
glycosylated PD-L1 should result in ER stress via the 
integrated networks of aggresome, proteasome, and 
autophagy. Future studies are warranted to clarify 
whether, upon proteasome inhibition, the RSV-induced 
non-fully glycosylated (unstable) PD-L1 form might 
become polyubiquitinated [41] and undergo selective 
degradation via the autophagy-lysosomal pathway; and 
3). Lastly, the glycosylation-targeted regulatory 
mechanism of RSV prevents the complete translocation 
of the fully-glycosylated population of PD-L1 to the cell 
membrane and, because the interaction between PD-L1 
and PD-1 is modulated specifically by N-linked 
glycosylation [50], abrogates the binding of PD-1 to PD-
L1, thereby providing a mechanism to switch on T-cell 
activity. Accordingly, impedance-based real-time 
analysis showed that cytotoxic T-lymphocyte activity 
was dramatically augmented when PD-L1-over-
expressing JIMT-1 cancer cells were previously exposed 
to RSV.  
 
Our findings might provide a foundation to exploit the N-
glycan biosynthesis-targeted inhibitory activity of RSV 
as a new strategy to safely alter PD-L1 glycosylation in 
vivo. Although targeting the surface distribution of PD-
L1 by modulating N-glycan branching is emerging as an 
exciting approach to boost the immune system against 
cancer cells [50, 83–85], the clinical development of 
currently existing inhibitors that impact processing or 
“trimming” of the glucosylated, high-mannose side 
chains by inhibiting one or more of the specific 
processing glycosidases/mannosidases, is still lacking 
regarding effective modifications capable of improving 
their therapeutic efficacy, selectivity, potency, and 
tolerability. Acknowledging the poor bioavailability 
(<1%) of orally-administered RSV [86, 87], the capacity 
of RSV-like strategies to target N-glycan branching of 
PD-L1 and, consequently, decrease the T-cell cyto-
toxicity threshold via targeting of glycoprotein-
processing enzymes such as GAA and α-Man I might be 
a potential treatment option for cancer patients exhibiting 
a high neo-antigen, immunologically-active phenotype 
capable of attracting immune cells that ultimately triggers 
an unsuccessful tumor-immune cell interaction via PD-
L1/PD-1 engagement [24–29, 88–90]. Early studies by 
Lucas et al. [91] showed that various colorectal and 
breast cancer cells (e.g., low PD-L1-expressing BT-474 
and SK-Br3 cell lines) exposed to high concentrations of 
RSV upregulated PD-L1. The authors claimed that a 
potential upregulation of PD-L1 in vivo by RSV would 
render tumor cells more sensitive to immune checkpoints 
targeting PD-L1 [91], a counterintuitive hypothesis in 
terms of the potential chemopreventive value of RSV 
when considering that a putative upregulation of PD-L1 
by RSV could enable pre-cancerous lesions to avoid 
antitumor immunity. Chin et al. [92] reported that the 
ability of the thyroid hormone L-thyroxin (T4) to inhibit 
the anti-cancer effects of RSV involves the up-regulation 
of PD-L1; conversely, RSV was found to down-regulate 
PD-L1 expression. A complex interplay thus exists 
between RSV and PD-L1 that might present mutually 
antagonistic effects and might differentially occur in 
settings where baseline PD-L1 is low or high [92, 93]. 
Baseline PD-L1 expression differs according to the 
molecular phenotype of breast carcinomas, with the 
highest expression occurring in those with basal-like 
traits and the lowest expression in those with luminal 
traits [40, 43, 44]. Each breast cancer subentity responds 
differentially to extrinsic and intrinsic factors, and a 
significant heterogeneity in PD-L1 expression can be 
observed even within PD-L1-overexpressing breast 
cancer populations. Thus, whereas PD-L1 upregulation 
might represent a protective mechanism against RSV in 
low PD-L1-expressing cancer cells, constitutive PD-L1 
ovexpressors could possess an inherent susceptibility to 
glycosylation defects under ER stress conditions imposed 
by GAA/α-Man-I inhibitors such as RSV. Accordingly, 
inhibition of N-linked glycosylation by RSV has been 
shown to trigger ER-mediated apoptosis in ovarian 
cancer cells [49]. Perhaps more importantly, RSV has 
been recently shown to induce immunogenic cell death 
and immune activation in terms of increased cytotoxic T-
cells, and to potentiate the therapeutic outcomes of a PD-
1 antibody in murine and human models of ovarian 
cancer [94]. These immunomodulatory actions of RSV in 
the tumor microenvironment, together with its ability to 
interfere with the glycosylation-driven stability of the 
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immune checkpoint PD-L1, provides experimental 
evidence in support of combining RSV, which is virtually 
nontoxic with respect to its systemic effects, with 
immune checkpoint inhibitors, and might form the basis 
of future clinical trials.  
 
Based on its mode of action involving core machineries 
(SIRT1 and AMPK) causally involved in the hallmarks 
of aging, such as epigenetic alterations, deregulated 
nutrient sensing, or mitochondrial dysfunction [62, 95], 
RSV has classically been considered an archetype 
member of the downstream type of calorie restriction 
mimetics (CRMs) including rapamycin, metformin, and 
polyamines (spermidine). Intriguingly, because normal 
human aging is characterized by a progressive decline 
in immune surveillance that is accompanied by PD-L1 
upregulation to favor cancer initiation and progression 
even in the absence of a more complex mutational 
landscape [96–100], the suppression of PD-L1 signaling 
via direct targeting of PD-L1 glycosylation enzymes 
could represent a new immunometabolic mechanism 
through which RSV might prevent immune dysfunction 
and cancer development in the context of aging. 
Although there are conflicting data about whether the 
SIRT1 agonist activity of RSV might alleviate glucose 
intolerance in humans, it is reasonable to suggest that 
the ability of RSV to mimic acarbose in enhancing anti-
cancer T-cell immunity [101, 102] uncovers an 
immunologic dimension to the previously observed 
capacity of RSV to exert anti-diabetic effects via direct 
inhibition of GAA [51–54, 103–105]. Acarbose, a 
pseudo-tetrasaccharide used to manage type 2 diabetes 
and a candidate drug in clinical trials targeting human 
aging based on its ability to improve health and lifespan 
in animal models [60–63, 106], is a potent competitive 
inhibitor of mammalian GAA, but is less effective 
against yeast GAA [51, 107]. RSV, however, has been 
shown to exert strong inhibition against both yeast and 
mammalian GAA activities [51, 53]. Although these 
discrepancies might be attributed to structural 
differences of the yeast and mammalian forms of the 
enzymes, we lack mechanistic insights capable of 
explaining the inhibition of GAA by RSV even at very 
low, clinically-relevant doses. In our hands, it was 
noteworthy that whereas RSV was in silico predicted to 
occupy the catalytic binding site of the yeast form of 
GAA with a higher binding energy than that predicted 
for acarbose, our computational model for human GAA 
predicted that the top binding modes of RSV localized 
distal to the catalytic residues in the active site pocket of 
GAA, thereby supporting a non-competitive mechanism 
via occupancy of GAA allosteric sites. Moreover, in 
silico modeling predicted the ability of RSV to operate 
as a kifunensine-like molecule capable of competitively 
occupying the catalytic site of the α-Man I enzyme, 
altogether offering an unforeseen mechanistic scenario 
linking the early recognized capacity of N-linked 
glycosylation to influence lifespan with the ability of 
RSV to directly block GAA and α-Man and activate an 
ER stress (dietary restriction-like) response [108, 55, 
56]. Therefore, from an immunomodulatory perspec-
tive, our present findings propose that RSV might 
unexpectedly operate as a member of the upstream-type 
of CRMs, which employ a mechanism of action 
involving direct targeting of glucose metabolism (i.e., 
inhibition of class I glycosydases) and transmit a signal 
in the upstream direction to mimic CR. 
 
Cancer immunomodulation involves the use of synthetic 
or natural agents capable of activating the immune 
response to impede tumor cell dissemination. The 
nutraceutical RSV, a natural polyphenolic phytoalexin 
that is present in red wine, red grape skin, berries, 
peanuts, and other natural sources, has recently been 
proposed as a cancer immunomodulatory molecule by 
either acting on immune cells or by sensitizing tumor 
cells to the cytotoxic effects of immune cells [109]. Our 
impedance-based real-time cell analysis showing that 
cytotoxic T-lymphocyte activity is dramatically 
exacerbated when highly aggressive cancer cells 
overexpressing PD-L1 in almost 100% of the cells were 
previously exposed to RSV strongly suggests that, 
beyond promoting abnormal PD-L1 glycosylation, RSV 
might be targeting the immunosuppressive signaling of 
PD-L1 by additional mechanisms. Computer-aided 
docking/MD simulations predicted the ability of RSV to 
locate at the center of the PD-L1 homodimer, filling a 
deep hydrophobic pocket that contributes multiple 
additional interactions between the PD-L1 monomers. 
Indeed, RSV was predicted to almost perfectly occupy 
the target space of Bristol-Myers Squibb (BMS)-
developed nonpeptidic chemical inhibitors such as 
BMS-8, BMS-202, or BMS-1166, which have a 
common scaffold and interact with the cavity formed by 
two PD-L1 monomers, (consisting of Ile54, Tyr56, 
Met115, Ile116, Ala121, and Tyr123 [71, 77]), thereby 
blocking the PD-1/PD-L1 interaction by inducing PD-
L1dimerization. The double-strike PD-1/PD-L1 
immune checkpoint inhibitor-like behavior of RSV 
based on its ability to directly target PD-L1 either via 
key post-translational modifications such as N-linked 
glycosylation [110–114] or via direct binding to PD-L1 
to block PD-1 binding [71–77] interferes with PD-L1 
stability and trafficking, impedes the correct targeting of 
PD-L1 to the cancer cell plasma membrane, and lastly 
elicits considerably enhanced cytotoxic T-lymphocyte 
immune-surveillance against tumor cells (Figure 9). 
This unforeseen immunomodulating mechanism of 
RSV might provide new approaches to restore T-cell 
function by targeting the PD-1/PD-L1 immunologic 
checkpoint with natural polyphenols.  
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MATERIALS AND METHODS 
 
Cell lines and culture conditions 
 
JIMT-1 cells were obtained from the German Collection 
of Microorganisms and Cell Culture (Braunschweig, 
Germany) and grown in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; BioWhittaker Inc., 
Walkersville, MD), 1% L-glutamine, 1% sodium 
pyruvate, 50 U/mL penicillin, and 50 μg/mL strep-
tomycin. MDA-MB-231 breast cancer cells were obtained 
from the American Type Culture Collection (Manassas, 
VA) and grown in Improved MEM (IMEM; BioSource 
International, Camarillo, CA) supplemented as above. All 
cells were maintained at 37°C in a humidified atmosphere 
of 95% air and 5% CO2. Cells were screened periodically 
for  Mycoplasma contamination. 
 
Approximately 250,000 cells were seeded in 60-mm 
dishes and treated with 100 μmol/L RSV (R5010), 5 
mmol/L metformin (D150959), 100 μmol/L phenformin 
(P7045) (all from Sigma-Aldrich, St Louis, MO), 100 
nmol/L soraphen A (kindly provided by Drs. Klaus 
Gerth and Rolf Jansen, Hemholtz Zentrum für 
Infektionsforschung GmbH, Braunschweig, Germany), 
5 μg/mL C75 (C5490; Sigma-Aldrich), 200 nmol/L 
PP242 (S2218; Selleckchem, Houston, TX), 200 
nmol/L Torin 2 (S2817; Selleckchem), 500 μmol/L 
AICAR (Cat. # sc-200659; Santa Cruz Biotechnology, 
Santa Cruz, CA), 5 μmol/L compound C (S7840, 
Selleckchem), 5 μg/mL tunicamycin (sc-3506, Santa 
Cruz Biotechnology), 20 μmol/L cycloheximide (sc-
3508, Santa Cruz Biotechnology), 1 μmol/L MG-132 
(S2619, Selleckchem), 10 μmol/L chloroquine (C6628,  
Sigma-Aldrich), 10 μmol/L EX-527 (S1541, 
Selleckchem), 10–50 μmol/L AR-A014418 (S7435, 
Selleckchem), or 20 mmol/L LiCl (L5509, Sigma-
Aldrich) as single agents or in combination, as 
specified. In parallel, the untreated cultures were used 




Following treatment with the above-mentioned drugs, 
cells were lysed in 2% SDS, 1% glycerol, and 5 mmol/L 
Tris-HCl, pH 6.8. Samples were sonicated for 1 min 
(under ice water bath conditions) with 2 s sonication 
and 2 s intervals to fully lyse cells and reduce viscosity. 
Alternatively, cell samples were extracted with lysis 
buffer (150 mmol/L NaCl, 50 mmol/L Tris-HCl pH 7.4, 
1 mmol/L EDTA, 1% Triton-X 100, 1 mmol/L 
phenylmethylsulfonyl fluoride, 1 mmol/L Na3VO4) and 
then incubated in the presence or absence of either 
PNGase F (P0704S, 1,000 Units/reaction) or Endo H 
(P0702S, 2,000 Units/reaction) (both from New 
England Biolabs, Ipswich, MA) for 2 h at 37°C using 30 
μg of total protein per reaction. Protein content was 
determined by the Bradford protein assay (Bio-Rad, 
Hercules, CA). Sample buffer was added to extracts and 
boiled for 4 min at 100°C. Equal amounts of cellular 
protein were electrophoresed on 12% SDS-PAGE gels, 
transferred to nitrocellulose membranes, and incubated 
with antibodies against PD-L1 (E1L3N® XP® Rabbit 
mAb #13684), SIRT1 (C14H14 Rabbit mAb #2496), or 
acetyl-p53 (Lys382) (antibody #2525) (all from Cell 
Signaling Technology, Danvers, MA), followed by 
incubation with a horseradish peroxidase-conjugated 
secondary antibody, and chemiluminescence detection. 
Vinculin (sc-25336; Santa Cruz Biotechnology; 
1:10,000 dilution) and β-actin (Cat. # 66009-1-Ig, Clone 
#: 2D4H5; Proteintech Group, Inc., Rosemont, IL) were 




Cells were seeded onto glass coverslips, treated with 
RSV for 24 h and then fixed with 4% paraformaldehyde 
in phosphate buffered saline (PBS). Following fixation 
at room temperature (RT) for 5 min, cells were 
permeabilized with 0.1% Triton X100/PBS. The 
coverslips were then placed in the antibody solution 
(E1L3N® XP® Rabbit mAb #13684 1:1,00 dilution or 
PD-L1 extracellular domain specific E1J2J rabbit mAb 
#15165 1:1,00 dilution, both from Cell Signaling 
Technology) and incubated for 60 min at RT. Cells 
were washed and stained with a secondary antibody. 
Cell nuclei were counterstained with Hoechst 33342. 
Images were captured using an Eclipse 50i fluorescence 
microscope equipped with NIS-Elements imaging 




Acidic human α-glucosidase (UniProt code: Q16706, 
PDB code: 5NN4), human ER α-mannosidase I (UniProt 
code: Q9UKMT, PDB code: 5KIJ), Saccharomyces 
cerevisiae α-glucosidase (UniProt code: P53008, PDB 
code: 4J5T), and PD-L1 (UniProt code: Q9NZQ7, PDB 
code: 5J89) crystallographic structures were obtained 
from the Research Collaboratory for Structural 
Bioinformatics (RCSB) Protein Data Bank (PDB). In the 
case of the human α-mannosidase II (UniProt code: 
Q16706), which lacks a high-resolution available PDB 
structure, a homology model was generated employing 
the 1QWU structure (a 1.2-Å resolution structure for the 
Golgi α-Man II from Drosophila melanogaster) as a 
template. The specific edition of protein structures was 
made using PyMol software (PyMOL Molecular 
Graphics System, v2.3.3 Schrödinger, LLC, at 
http://www.pymol.org/) without further optimization.  
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Molecular docking experiments were carried out using 
YASARA v19.9.17 software executing the AutoDock 
4 algorithm with AMBER99 as a force field [115–
118]. Briefly, a total of 999 flexible docking runs were 
set and clustered (7 Å) around the putative binding 
sites, that is, two complexed compounds belong to 
different clusters if the ligand Root-Mean-Square 
Deviation of their atomic positions is greater than a 
minimum of 7 Å around certain hot spot 
conformations. The YASARA pH command was set to 
5.0, 7.2, 7.2, and 6.4 when running the molecular 
docking simulations of acidic human α-glucosidase, 
human ER α-mannosidase I, S. cerevisiae α-
glucosidase, and human Golgi α-mannosidase II 
homology model, respectively. The YASARA 
software calculated the Gibbs free energy variation 
(ΔG, kcal/mol), with more positive energy values 
indicating stronger binding. To calculate this 
parameter, Autodock Vina uses a force field scoring 
function that considers the strength of electrostatic 
interactions, hydrogen bonding between all atoms of 
the two binding partners in the complex, 
intermolecular van der Waals forces, and also 
solvation and entropy contributions [119]. All the 
values are included in the corresponding tables with a 
negative sign. Only the ΔG value for the best RSV 
docked in each cluster is shown. Dissociation 
constants were recalculated from the average binding 
energy of all RSVs of each cluster. The number of 
RSV docked molecules in each cluster was identified 
as “members” (in percentages). 
 
Molecular dynamics simulations 
 
YASARA dynamics v19.9.17 was used for all the MD 
simulations with AMBER14 as a force field. The 
simulation cell was allowed to include 20 Å 
surrounding the protein and filled with water at a 
density of 0.997 g/mL. Initial energy minimization 
was carried out under relaxed constraints using 
steepest descent minimization. Simulations were 
performed in water at constant pressure-constant 
temperature (25°C) conditions. To mimic physio-
logical conditions, counter ions were added to 
neutralize the system; Na+ or Cl- were added in 
replacement of water to give a total NaCl con-
centration of 0.9% and pH was maintained at 7.4. 
Hydrogen atoms were added to the protein structure at 
the appropriate ionizable groups according to the 
calculated pKa in relation to the simulation pH (i.e., a 
hydrogen atom will be added if the computed pKa is 
higher than the pH). The pKa was computed for each 
residue according to the Ewald method [120]. All 
simulation steps were run by a preinstalled macro 
(md_run.mcr) within the YASARA suite. Data were 
collected every 10 ps. The molecular mechanics/ 
Poisson-Boltzmann surface area (MM/PBSA) was 
implemented with the YASARA macro 
md_analyzebindenergy.mcr to calculate the binding 
free energy with solvation of the ligand, complex, and 
free protein, as previously described [121–123].  
 
All of the figures were prepared using PyMol 2.0 
software and all interactions were detected using the 
PLIP algorithm [124].  
 
Human T-cell culture 
 
To acquire activated T-cells, human peripheral blood 
mononuclear cells (Cat. #70025) were cultured in 
ImmunoCult-XF™ T cell expansion medium (Cat. 
#10981) containing ImmunoCult-XF™ Human 
CD3/CD28/CD2 T-cell activator (Cat. #10971) (all 
from StemCell Technologies, Vancouver, BC, 
Canada), and 10 ng/mL IL-2 (Cat. #200-02; 
PeproTech, Rocky Hill, NJ) for one week, as per the 
manufacturers’ instructions. 
 
Cytolytic T-cell assay 
 
T-cell-mediated lysis of tumor cells was monitored 
using an impedance-based approach. One hundred 
microliters of DMEM containing 10% FBS was added 
to each well of an E-Plate 16 (Roche Applied 
Sciences, Indianapolis, IN). Background impedance 
was measured using the xCELLigence RTCA 
instrument (Roche) at 37°C and 5% CO2. Tumor cells 
were harvested, counted, and resuspended at a density 
of 5 × 104 cells/mL in DMEM with 10% FBS, and 100 
μL of the tumor cell suspension was added to each 
well of the E-Plate 16. Impedance was measured every 
5 minutes for approximately 24 h, as described. Media 
from E-Plate 16 wells were removed and replaced with 
unsupplemented culture media in control wells or 
media containing 100 μg/mL RSV in experimental 
wells, and impedance was measured every 5 minutes 
for approximately 24 h. T-cells were counted and 
resuspended at a concentration of 5 × 105 cells/mL in 
DMEM including an antii-CD3 antibody (Cat. #16-
0037, 100 ng/mL; eBioscience, Thermo Fisher 
Scientific Inc., Philadelphia, PA). One hundred 
microliters of the T-cell suspension or media alone 
was added to respective wells and impedance was 
measured every 5 minutes for an additional 24 h. T-
cell-mediated cell death of tumor cells was monitored 
in real-time and indicated as a decrease in the so-called 
cell index (CI) obtained using RTCA Software 1.2 
(Acea Biosciences, San Diego, CA). Results were 
normalized to 1 to 2 h following T-cell addition. 
Cytolytic activity was calculated as the percentage of 
cytolysis 5 and 10 hours after the normalization time 
(=[CIno effector-CIeffector]/CIno effector × 100).  
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Statistical analysis 
 
Cytolytic activity means were compared using a two-
way ANOVA with Sidak’s multiple comparison post-
test. Results were designated significant when the P-
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Supplementary Figure S1. Trajectories and MM/PBSA free energy analysis of RSV (left) and acarbose (right) forming 
complexes with the yeast form of GGA. 




Supplementary Figure S2. Trajectories and MM/PBSA free energy analysis of RSV clusters forming complexes with human 
GAA (A), yeast GGA (B), human α-Man I (C), and human α-Man II homology model (D). 
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Supplementary Tables 
 
Supplementary Table S1. Details of the interaction of RSV docked to yeast α-glucosidase. 
 
Cluster number ∆G, [kcal/mol] Dissoc. constant, [µM] Members 
1 -7.89 1.650 2.9% 
2 -7.43 3.590 4.1% 
3 -7.28 4.640 6.9% 
4 -7.08 6.420 2.6% 
5 -6.78 10.770 1.8% 
6 -6.76 11.160 2.3% 
7 -6.66 13.160 1.9% 
8 -6.64 13.540 1.4% 
9 -6.55 15.870 4.1% 
10 -6.53 16.310 2.9% 
11 -6.43 19.360 3.8% 
12 -6.33 22.950 3.8% 
13 -6.30 24.190 1.3% 
14 -6.27 25.250 3.2% 
(Uniprot code: P53008, PDB code: 4J5T). For the best-docked RSV molecule of each cluster,  
the Gibbs free energy (∆G, Kcal/mol), the dissociation constant, and the number of molecules 
 members (as %) are shown. 
 
Supplementary Table S2. Details of the interaction of RSV docked to human α-glucosidase. 
 
Cluster number ∆G, [kcal/mol] Dissoc. constant, [µM] Members 
1 -8.04 0.128 3.1% 
2 -7.78 0.197 1.7% 
3 -7.66 0.242 1.4% 
4 -7.37 0.399 0.9% 
5 -7.34 0.420 1.7% 
6 -7.28 0.462 3.0% 
7 -7.28 0.461 1.0% 
8 -7.02 0.710 2.1% 
9 -6.78 1.077 0.8% 
10 -6.73 1.166 1.3% 
11 -6.72 1.193 1.1% 
(Uniprot code: P10253, PDB code: 5NN4). For the best-docked RSV molecule of each cluster, 
the Gibbs free energy (∆G, Kcal/mol), the dissociation constant, and the number of molecules 
members (as %) are shown. 
www.aging-us.com 34 AGING 
Supplementary Table 3. Details of the interaction of RSV docked to human α-mannosidase I. 
 
Cluster number ∆G, [kcal/mol] Dissoc. constant, [µM] Members 
1 -8.25 0.892 2.1% 
(Uniprot code: Q9UKM7, PDB code: 5KIJ). For the best-docked RSV molecule of each cluster, 
the Gibbs free energy (∆G, Kcal/mol), the dissociation constant, and the number of molecules 
 members (as %) are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
